People S Bank Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: People S Bank Pharmaceutical Import Records from India — 5 Products, $510.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

People S Bank — Pharmaceutical Importer Profile (2026) | 5 Products, $510.7K Trade | TransData Nexus

People S Bank

Pharmaceutical Importer · Sri Lanka · Cardiovascular Focus · $510.7K Total Trade · DGFT Verified

People S Bank is a pharmaceutical importer based in Sri Lanka with a total trade value of $510.7K across 5 products in 4 therapeutic categories. Based on 13 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. People S Bank sources from 21 verified Indian suppliers, with Innova Captab Limited accounting for 38.5% of imports.

People S Bank — Import Portfolio & Supplier Network

People S Bank import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to People S Bank?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Innova Captab Limited	$1.3M	83	38.5%
Micro Labs Limited	$617.4K	45	18.8%
United Biotech Private Limited

What Formulations Does People S Bank Import?

Formulation	Value	Ships
Pharma product: auxtocef 500	$472.2K	25
Pharma product:auxtocef 500	$469.3K	22
Pharma product:atornova	$162.2K	24
(bnoxiparin 40)Each prefilled syringe conts:enoxaparin sodium USP 40MG(porcine derived) water for injection USP qs.to	$150.0K	3
Amoxicillin capsules BP 500 MG erox	$123.4K	4
Gypsona -15cm x 2.7m roll plaster of	$100.0K	2
Oncotar 1000, cytarabine injection BP	$94.8K	4
Cefotaxime sodium for injection BP	$94.2K	2
Bactafuz b cream - 15 gms Each g	$91.7K	6
Pharma product:innotel-40 [telmisartan	$59.8K	5
Pharma product-ifomid m 1g with mesna	$50.0K	1
Other - indapamide sr TAB 1.5MG tablet	$50.0K	1
Gypsona plaster of paris bandage, b.p.(1988) (p.o.p. bandage) size : 15cm x 2.7m	$50.0K	1
Harmless medicines for human consumption-.;" azathioprine tablets bp50 MG (1 x 10 TAB.)	$50.0K	1
Actilyse, drinj/1/50MG (Each Pack contains alteplase 50MG, recombinant human tissue-type plasminogen activator	$50.0K	1

People S Bank imports 90 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Enoxaparin	Cardiovascular	$150.0K	3	0.1%	14
2	Syringe	Medical Devices & Diagnostics	$150.0K	3	0.1%	17
3	Diltiazem	Cardiovascular	$100.0K	2	0.6%	16
4	Teicoplanin	Advanced Antibiotics	$100.0K	2	1.6%	7
5	Vinblastine	Oncology	$10.7K	3	1.4%	8

People S Bank imports 5 pharmaceutical products across 4 categories into Sri Lanka totaling $510.7K.

People S Bank — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

People S Bank is a state-owned commercial bank headquartered in Colombo, Sri Lanka. Established in 1961, it operates under the ownership of the Ministry of Finance. The bank offers a comprehensive range of financial services, including retail and corporate banking, trade finance, and foreign exchange. With a network of 747 branches as of 2024, People's Bank plays a pivotal role in Sri Lanka's financial sector.

In addition to its core banking operations, People's Bank has a dedicated International Banking Division that handles trade services, including the importation of pharmaceutical products. This division facilitates the procurement of essential medicines and medical devices, ensuring a steady supply to meet the country's healthcare needs. The bank's involvement in pharmaceutical imports underscores its commitment to supporting Sri Lanka's healthcare infrastructure.

2Distribution Network

People S Bank's distribution network for pharmaceutical imports is managed through its International Banking Division, which coordinates with various suppliers and logistics partners to ensure efficient delivery of products. While specific warehouse locations are not publicly disclosed, the bank's extensive branch network across Sri Lanka facilitates the distribution of imported pharmaceuticals to healthcare facilities nationwide. The logistics capabilities are designed to handle the complexities of pharmaceutical supply chains, ensuring timely and compliant delivery of products.

3Industry Role

Within Sri Lanka's pharmaceutical supply chain, People's Bank functions as a logistics intermediary. By importing pharmaceutical products, the bank ensures that essential medicines and medical devices are available to meet the country's healthcare demands. Its role is crucial in bridging the gap between international suppliers and local healthcare providers, thereby contributing to the overall efficiency and effectiveness of the pharmaceutical distribution system in Sri Lanka.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — People S Bank

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

People S Bank's pharmaceutical imports are sourced from a diverse array of Indian suppliers, with 21 unique suppliers recorded in the customs data. The top five suppliers—Innova Captop Limited, Micro Labs Limited, United Biotech Private Limited, Essity India Private Limited, and Brawn Laboratories Limited—account for a significant portion of the total import value. This indicates a strategic approach to sourcing, balancing the need for reliable supply with the benefits of supplier diversification. The presence of multiple suppliers suggests a deliberate effort to mitigate risks associated with single-source dependency, enhancing the stability and resilience of the supply chain.

2Supply Chain Resilience

The resilience of People's Bank's Indian supply chain is bolstered by its engagement with multiple suppliers, reducing the impact of potential disruptions from any single source. The diversity in product formulations—90 unique formulations imported—further enhances supply chain robustness by spreading risk across various products. While specific details about backup suppliers and shipping routes are not publicly available, the bank's established relationships with reputable Indian pharmaceutical companies and its adherence to regulatory compliance standards suggest a well-structured and resilient supply chain.

Strategic Implications

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing pharmaceutical imports in Sri Lanka. Established under the NMRA Act No. 5 of 2015, the NMRA is responsible for ensuring the safety, efficacy, and quality of medicinal products, medical devices, and borderline products. The authority operates under the Ministry of Health and is tasked with regulating the import, manufacture, and distribution of pharmaceuticals in the country. (nmra.gov.lk)

Key legislation governing pharmaceutical imports includes the NMRA Act No. 5 of 2015, which outlines the procedures for registration, import control, and market surveillance of medicinal products. The Medicines (Pricing Mechanism for Medicines) Regulations, as detailed in Gazette Extraordinary No. 2446/34, provide a standardized pricing formula for imported medicines, ensuring transparency and affordability.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Sri Lanka are stringent. All pharmaceutical products must be registered with the NMRA before importation. Import license applications should be submitted at least twelve weeks in advance to avoid delays. As of February 2026, the NMRA requires price submissions for import licenses expiring on or after 1st February 2026.

Good Manufacturing Practice (GMP) certification is mandatory for pharmaceutical imports. The NMRA recognizes GMP certificates from reputable authorities, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from these recognized bodies to comply with Sri Lankan regulations. (nmra.gov.lk)

People S Bank — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

People S Bank's focus on importing pharmaceuticals across therapeutic categories—Cardiovascular, Medical Devices & Diagnostics, and Advanced Antibiotics—aligns with the pressing healthcare needs in Sri Lanka. The substantial import values in these categories indicate a strategic approach to sourcing products that address critical health concerns. The demand for these products is driven by the prevalence of cardiovascular diseases, the need for advanced diagnostic tools, and the emergence of antibiotic-resistant infections in the country.

2Sourcing Profile

People S Bank's sourcing strategy emphasizes the importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs. This approach ensures that the bank provides ready-to-use medications that meet the immediate needs of healthcare providers. India's well-established pharmaceutical industry, with its adherence to international quality standards, makes it a preferred sourcing partner for these formulations.

3Market Positioning

By importing a diverse range of pharmaceutical products, People's Bank serves multiple segments of the Sri Lankan market, including retail pharmacies, hospitals, and government tenders. The bank's role as a logistics intermediary ensures that essential medicines and medical devices are accessible to various healthcare providers, thereby supporting the overall healthcare infrastructure in Sri Lanka.

Seller's Guide — How to Become a Supplier to People S Bank

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with People's Bank, given the bank's strategic sourcing pattern and its emphasis on supplier diversification. Potential gaps in the current sourcing include the need for specialized formulations or products that are not currently imported. Indian exporters can explore these opportunities by offering products that align with Sri Lanka's healthcare priorities and by ensuring compliance with the regulatory standards set by the NMRA.

2Requirements & Qualifications

Indian exporters aiming to supply People's Bank and the Sri Lankan market must ensure that their products are registered with the NMRA and comply with all import licensing requirements. Suppliers must hold valid GMP certifications from recognized authorities such as EU GMP, WHO GMP, or PIC/S. Additionally, products must meet the NMRA's quality standards, including batch testing and labeling requirements. Adherence to these standards is essential for successful market entry.

3How to Approach

Frequently Asked Questions — People S Bank

What products does People S Bank import from India?

People S Bank imports 5 pharmaceutical products across 4 categories. Top imports: Enoxaparin ($150.0K), Syringe ($150.0K), Diltiazem ($100.0K), Teicoplanin ($100.0K), Vinblastine ($10.7K).

Who supplies pharmaceuticals to People S Bank from India?

People S Bank sources from 21 verified Indian suppliers. The primary supplier is Innova Captab Limited (38.5% of imports, $1.3M).

What is People S Bank's total pharmaceutical import value?

People S Bank's total pharmaceutical import value from India is $510.7K, based on 13 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does People S Bank focus on?

People S Bank imports across 4 categories. The largest: Cardiovascular (48.9%), Medical Devices & Diagnostics (29.4%), Advanced Antibiotics (19.6%).

Get Full People S Bank Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.